OCS

NASDAQ 已收盘

Oculis Holding AG

7.44 USD
▲+0.05+0.68%
盘后 7.49 +0.73%
2026-11-19
市值
$435.83M
市盈率
—
EPS
-1.62
股息率
—
52 周区间
6.78 – 34.48
成交量
153.99K
Beta
0.29
目标价
35.81
52W 低 6.7852W 高 34.48
价格走势

公司简介

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da...